Enhanced Point-of-Care SARS-CoV-2 Detection: Integrating RT-LAMP with Microscanning.

Publication date: Jul 17, 2024

The COVID-19 pandemic has highlighted the urgent need for rapid and accurate diagnostic methods for various infectious diseases, including SARS-CoV-2. Traditional RT-PCR methods, while highly sensitive and specific, require complex equipment and skilled personnel. In response, we developed an integrated RT-LAMP-MS assay, which combines rapid reverse transcription loop-mediated isothermal amplification (RT-LAMP) with microscanning (MS) technology for detecting SARS-CoV-2. The assay uses magnesium pyrophosphate formed during LAMP amplification as a visual marker, allowing direct observation via microscopy without the need for additional chemical indicators or probes. For the SARS-CoV-2/IC RT-LAMP-MS assay, the sample-LAMP reagent mixture was added to a microchip with SARS-CoV-2 primers and internal controls, then incubated at 62 ^0C for 30 min in a heat block, followed by amplification analysis using a microscanner. In clinical tests, the RT-LAMP-MS assay showed 99% sensitivity and 100% specificity, which is identical to the RT-LAMP results and comparable to the commercial Allplex SARS-CoV-2 assay results. Additionally, the limit of detection (LOD) was determined to be 10 PFU mL (dynamic range: 10~10 PFU mL). The assay delivers results in 30 min, uses low-cost equipment, and demonstrates 100% reproducibility in repeated tests, making it suitable for point-of-care use in resource-limited settings.

Open Access PDF

Concepts Keywords
Biosensors COVID-19
Isothermal Humans
Magnesium magnesium pyrophosphate
Pandemic Molecular Diagnostic Techniques
Point-of-Care Systems
point-of-care testing
RNA, Viral
RNA, Viral
RT-LAMP
SARS-CoV-2
SARS-CoV-2
Sensitivity and Specificity
visual detection

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH infectious diseases
disease IDO assay
drug DRUGBANK Magnesium
disease MESH Emergency
disease VO Severe acute respiratory syndrome coronavirus 2
disease VO efficient
disease VO time
disease VO effectiveness
disease IDO site
drug DRUGBANK Coenzyme M
disease VO efficiency
disease IDO process
disease MESH viral infections
disease MESH Influenza
disease MESH parainfluenza
disease VO gene
drug DRUGBANK Medical air
disease VO volume
disease IDO production
disease VO USA
drug DRUGBANK Thiocolchicoside
drug DRUGBANK Trihexyphenidyl
disease VO Tat
drug DRUGBANK Timonacic
drug DRUGBANK 5-amino-1 3 4-thiadiazole-2-thiol
drug DRUGBANK 7-Methyl-Gpppa
disease VO Gag
drug DRUGBANK Ademetionine
drug DRUGBANK Albendazole
drug DRUGBANK Water
disease VO population
disease VO Viruses
disease MESH infection
disease VO effective
disease VO injection
disease MESH age related macular degeneration
disease VO Enterovirus
disease VO Respiratory syncytial virus
drug DRUGBANK Carboxyamidotriazole
drug DRUGBANK Nonoxynol-9
pathway REACTOME Infectious disease
disease IDO infectious disease
drug DRUGBANK Troleandomycin
disease MESH Hepatitis
disease IDO pathogen
disease VO device
disease MESH Syndrome
drug DRUGBANK Polyethylene glycol
drug DRUGBANK Gold
disease IDO blood
disease MESH Uncertainty

Original Article

(Visited 4 times, 1 visits today)